Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

Main Article Content

Mark Lebwohl
Icahn School of Medicine, Mount Sinai, New York, NY

Linda Stein Gold
Henry Ford Health System, Detroit, MI

Bruce Strober
Yale University, New Haven and Central Connecticut Dermatology Research, Cromwell, CT

April Armstrong
Keck School of Medicine University of Southern California, Los Angeles, CA

H Chih-Ho Hong
University of British Columbia and Probity Medical Research, Surrey, BC, Canada

Leon Kircik
Icahn School of Medicine, Mount Sinai, New York, NY; Skin Sciences, PLLC, Louisville, KY

Jennifer Soung
Southern California Dermatology, Santa Ana, CA

Jeff Fromowitz
Dermatology of Boca, Boca Raton, FL

Scott Guenthner
The Indiana Clinical Trials Center, PC, Plainfield, IN

Stephen Piscitelli
Dermavant Sciences, Inc., Durham, NC

David Rubenstein
Dermavant Sciences, Inc., Durham, NC

Philip Brown
Dermavant Sciences, Inc., Durham, NC

Anna Tallman
Dermavant Sciences, Inc., Durham, NC

Robert Bissonnette
Innovaderm Research Inc., Montreal, QC, Canada

Keywords

Psoriasis, Aryl Hydrocarbon Receptor Modulating Agent, Tapinarof, Safety, Efficacy

Abstract

Abstract not available.

References

1. Menter A, et al. J Am Acad Dermatol. 2008;58:826–850

2. Robbins K, et al. J Am Acad Dermatol. 2019;80:714–721

3. Stein Gold L, et al. J Am Acad Dermatol. 2020; doi: 10.1016/j.jaad.2020.04.181.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.75

Article Details

How to Cite
Lebwohl, M., Stein Gold, L., Strober, B., Armstrong, A., Hong, H. C.-H., Kircik, L., Soung, J., Fromowitz, J., Guenthner, S., Piscitelli, S., Rubenstein, D., Brown, P., Tallman, A., & Bissonnette, R. (2020). Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, 4(6), s75. https://doi.org/10.25251/skin.4.supp.75
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 9 10 11 12 13 14 15 16 17 18 > >>